Overview

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Status:
Active, not recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.

Phase:

Phase 1

Details

Lead Sponsor:

Allogene Therapeutics

Treatments:

Allopurinol
Cyclophosphamide
Fludarabine